Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Variation in Time to First Disease Modifying Therapy in people with MS in the United States, United Kingdom, and Germany (517)

Alexander Stahmann, David Ellenberger, Ruth-Ann Marrie, Rod Middleton, Richard Nicholas, Jeff Rodgers, Amber Salter
First published April 14, 2020,
Alexander Stahmann
1German MS-Register by DMSG, MSFP-gGmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ellenberger
1German MS-Register by DMSG, MSFP-gGmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth-Ann Marrie
2University of Manitoba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rod Middleton
3Swansea University Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Nicholas
4Imperial College Healthcare Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Rodgers
3Swansea University Medical School
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amber Salter
5Division of Biostatistics, Washington University in St. Louis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Variation in Time to First Disease Modifying Therapy in people with MS in the United States, United Kingdom, and Germany (517)
Alexander Stahmann, David Ellenberger, Ruth-Ann Marrie, Rod Middleton, Richard Nicholas, Jeff Rodgers, Amber Salter
Neurology Apr 2020, 94 (15 Supplement) 517;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To investigate the time to first Disease Modifying Therapy (DMT) after diagnosis in three large multiple sclerosis (MS) registry populations, NARCOMS, United Kingdom (UKMSR) and Germany (GMSR).

Background: The number of DMT options in MS has increased over time. Recent EAN/ECTRIMS guidelines have highlighted the need for early introduction of DMT. [Montalban et al. 2018] Still comparable data for the time from MS diagnosis till the start of the first DMT is scare.

Design/Methods: Each registry captures demographics, disability status (categorized as mild, moderate or severe) and treatment status. Inclusion criteria were a relapsing disease course, diagnosis in 2014–2018 and provided data on DMT and disability status. The overall and age-, gender- and disability-specific times to first DMT after diagnosis were summarized. Kaplan-Meier curves were used to examine the median time to first DMT (in years) and Cox regression models for covariates of interest (gender, age at diagnosis, disability) were performed. Participants were censored at the date of the last recorded visit. Comparisons between countries were evaluated in a meta-analytic approach.

Results: 2700 participants (NARCOMS:306, UKMSR:675, GMSR:1719) fulfilled the inclusion criteria. The overall median time to first DMT was shortest in Germany [0.21 (0.08, 0.78)] followed by the UK [0.55 (0.25, 2.33) ] and NARCOMS [1.0 (0.33, 1.00)]. 4.5 years after diagnosis, a vast majority (93.5%) of NARCOMS participants received a DMT where as in Germany 16.4% and more than 36.1 % in the UK have not received a DMT by that point. Cox regressions showed that higher age (61+) [p<0.001] and moderate disability [e.g. EDSS > 3 & < 6, p<0.035] are associated with a longer time to first DMT.

Conclusions: Time to first DMT varied across countries, however, a larger proportion of PwMS in NARCOMS did receive a DMT at last recorded visit within 5 years of diagnosis than in Germany and the UK.

Disclosure: Dr. Stahmann has received research support from Biogen, Celgene, Merck and Novartis.Dr. Ellenberger has nothing to disclose. Dr. Marrie has received personal compensation in an editorial capacity for SAGE Publications (MSJ-ETC).Dr. Middleton has nothing to disclose. Dr. Nicholas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Roche, Novartis. Dr. Nicholas has received research support from Biogen, Novartis and Roche. Dr. Rodgers has nothing to disclose. Dr. Salter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with I receive consulting for statistical reviews for Circulation: Cardiovascular Imaging..

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise